Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31383720 | 0.83 | TRPV4 (0.42) | TRPV4P2RX7KCNH2 | |
| SCHEMBL27196766 | 0.83 | TRPV4 (0.42) | TRPV4P2RX7KCNH2 | |
| SCHEMBL31698330 | 0.80 | P2RX7 (0.35) | TRPV4P2RX7CNR2 | |
| SCHEMBL13646216 | 0.79 | DRD2 (0.51) | DRD2P2RX7KCNH2 | |
| SCHEMBL180972 | 0.78 | SYK (0.40) | DRD2KCNH2 | |
| Hydrochloric Acid SCHEMBL2885444 | 0.78 | DRD2 (0.50) | DRD2P2RX7KCNH2 | |
| SCHEMBL20753967 | 0.77 | DRD2 (0.42) | DRD2 | |
| SCHEMBL1750265 | 0.76 | DRD2 (0.61) | DRD2 | |
| SCHEMBL653874 | 0.75 | DRD2 (0.59) | DRD2KCNH2 | |
| Hydrochloric Acid SCHEMBL23578391 | 0.73 | DRD2 (0.58) | DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-26 | — | — | US | disclosed |
| EP-4563574-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630649-A | Nitrogen-containing saturated heterocyclic derivative | 住友制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | disclosed |
| WO-2024024962-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | 住友ファーマ株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | DRD2 738/4885TRPV4 3938/4885P2RX7 1856/4885 |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | DRD2 179/4885TRPV4 560/4885P2RX7 198/4885 |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | DRD2 738/4885TRPV4 3938/4885P2RX7 1856/4885 |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | DRD2 738/4885TRPV4 3938/4885P2RX7 1856/4885 |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | DRD2 738/4885TRPV4 3938/4885P2RX7 1856/4885 |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | DRD2 738/4885TRPV4 3938/4885P2RX7 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.